Previous 10 | Next 10 |
Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023 PR Newswire HOLON, Israel , Feb. 13, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational tar...
Compugen to Present at the SVB Securities Global Biopharma Conference PR Newswire HOLON, Israel , Feb. 9, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...
Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview PR Newswire HOLON, Israel , Jan. 23, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target disco...
Shares of Compugen (NASDAQ: CGEN) rose as much as 18.5% on Thursday. The stock closed at $0.6524 on Wednesday and opened at $0.70 on Thursday, rising to a daily high of $0.77 around 2:30 p.m. EST before coming down quite a bit, to $0.68, at the close. The stock is down more than 83% so fa...
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer PR Newswire COM701 in combination with nivolumab ± BMS-986207 (anti-TIGIT) in heavil...
Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients PR Newswire At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 (anti-TIGIT) demonstra...
Shares of Compugen (NASDAQ: CGEN) , a clinical-stage biotech company that specializes in immunology therapies to treat cancer, saw its shares rise 16.5% on Wednesday. The stock closed on Tuesday at $1.03, then opened on Wednesday at $1.01, before jumping to $1.23 in the late afternoon and...
Compugen to Participate in the JMP Securities Hematology and Oncology Summit PR Newswire HOLON, Israel , Nov. 29, 2022 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discove...
Shares of Compugen (NASDAQ: CGEN) rose 17.86% on Thursday. The clinical-stage immunotherapy pharmaceutical company focuses on oncology therapies and uses artificial intelligence to find new drug targets and biological pathways for cancer therapies. The stock closed on Wednesday ...
News, Short Squeeze, Breakout and More Instantly...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...